Gary A. Lyons

Gary A. Lyons has been a member of HCR’s SAB since 2018.  HCR utilizes Mr. Lyons’ decades-long experience as a CEO and senior manager in the biopharmaceutical sector to evaluate potential products of interest particularly on the West Coast.  Mr. Lyons has more than 35 years of industry experience, including as Chief Executive Officer of Neurocrine Biosciences, Inc., a position he held from 1993 through 2008.  Mr. Lyons remains on the Board of Directors of Neurocrine.  Prior to Neurocrine, Mr. Lyons held several senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales.  While at Genentech, Mr. Lyons also served as a member of the company’s Executive Committee and was responsible for international licensing, acquisitions and partnering for Genentech’s Corporate Venture Program. Mr. Lyons currently serves on the Board of Directors of Vical, Inc., Cytori Therapeutics, Inc., and Novus Therapeutics and is the Chairman of the Board of Directors of both Rigel Pharmaceuticals, Inc. and Retrophin, Inc.  He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from the Kellogg School of Management at Northwestern University.